Juvenile-Onset Recurrent Respiratory Papillomatosis (JORRP)

Definition

Epidemiology

• Two distinct age peaks exist: the juvenile form (onset <5 years) and the adult form (20–40 years). The juvenile form is more aggressive.
• Rare but impactful: although uncommon, the disease burden per patient is immense — over 100 surgical procedures may be required during a child's lifetime.
• Following widespread HPV vaccination, a significant decline in JORRP incidence has been documented in countries with national vaccination programs (2025 systematic review, PMID 39611396).
• Cummings Otolaryngology Head and Neck Surgery, p. 1131

Etiology and Virology

• HPV subtypes 6 and 11 account for the vast majority of cases.
• HPV-11 is associated with:
  • More aggressive disease
  • More frequent surgical interventions
  • Higher risk of tracheopulmonary spread
• HPV-16 and -18 are occasionally found and carry higher risk of malignant transformation to squamous cell carcinoma.
• Transmission occurs via the birth canal from a mother with genital condylomata; however:
  • Only ~1 in 400 exposed children actually develop RRP (low infectivity)
  • 7 per 1,000 births to genitally infected mothers develop RRP
  • Cesarean section is NOT reliably protective — its use in this context remains controversial.
  • Germline transmission from parents with RRP to children appears rare.

Pathology and Histology

Histologic features:

• Exophytic, papillary fronds with fibrovascular cores
• Acanthosis — thickened stratified squamous epithelium
• Koilocytes — pathognomonic HPV-infected cells with perinuclear halos and irregular nuclei in the superficial layers
• No invasion of the underlying basement membrane (distinguishes from carcinoma)
• Focal parakeratosis

Clinical Presentation

• Hoarseness — most common initial symptom (voice change)
• Stridor — inspiratory, from laryngeal obstruction
• Dyspnea, respiratory distress
• Recurrent croup-like episodes — leading to frequent misdiagnosis as asthma or reflux
• Chronic cough, feeding difficulties

Endoscopic Appearance

1. Classic exophytic — cauliflower-like, friable, white-pink irregular masses, sessile or pedunculated
2. Carpet variant — velvety, flat growth with stippled red dots (fibrovascular cores); frequently misdiagnosed as acid reflux; more common in adults

Staging and Severity Assessment

• Grades extent of papillomatosis at defined anatomic subsites throughout the aerodigestive tract
• Enables objective monitoring of disease progression over time
• Guides surgical planning and communication between clinicians

• Early age at onset (strongest predictor — more important than HPV type alone)
• HPV-11 positivity
• Low socioeconomic status
• Maternal condyloma history during pregnancy
• High number of prior surgeries (positively correlated with tracheal spread)

Distal Spread

• Correlated with: tracheotomy history, high surgical frequency, long disease duration
• Chest CT at diagnosis is recommended; repeat every 5 years if initial scan is normal and no bronchial progression
• Pulmonary involvement can cause cystic changes, pneumonia, respiratory failure

Management

1. Surgical — Gold Standard

• Do NOT strip both vocal folds simultaneously — avoids anterior commissure scarring
• Tracheotomy is discouraged: promotes distal spread, should be avoided if possible
• Children may require >100 surgeries over childhood; some require procedures every few weeks

2. Adjuvant Medical Therapies

Cidofovir (intralesional)

• Cytosine nucleoside analogue antiviral
• Most strongly supported by systematic reviews of English literature
• Injected intralesionally at time of surgery
• Reduces recurrence interval; well-studied in pediatric series
• Concerns regarding potential carcinogenicity at high doses

Interferon (alpha)

• Dramatic responses in some patients; limited long-term role
• Papillomas tend to regrow on cessation
• Higher doses/longer duration → higher response rate (Leventhal criteria)
• ~25% achieve long-term remission; most have reduced growth rate
• Used when disease is severe and refractory to surgical control alone

Bevacizumab (systemic)

• Anti-VEGF (vascular endothelial growth factor) monoclonal antibody
• Shown promise in aggressive cases, particularly with tracheopulmonary spread
• Image below shows regression of laryngeal and endobronchial papillomas after systemic bevacizumab therapy

Indole-3-Carbinol

• Natural derivative from cruciferous vegetables (broccoli, cabbage)
• Anecdotal evidence of benefit; likely more effective in rapidly growing disease
• Some authors report disappointing results

Methotrexate

• Used in refractory cases not responding to interferon or cis-retinoic acid
• Prolonged inter-surgical interval and reduced disease severity reported; no complete regression

HPV Vaccine (Gardasil / Gardasil 9) — Adjuvant Use

• Multiple studies support HPV vaccination as adjuvant treatment in JORRP
• Mechanism unclear (prophylactic vaccine used therapeutically) — likely prevents reinfection after surgical removal
• 2022 systematic review supports potential benefit in reducing recurrence
• 2024 retrospective cohort (19-year data) continues to show benefit in prolonging surgical intervals
• Recommended by international IPOG (International Pediatric Otolaryngology Group) consensus

Photodynamic therapy / Cryotherapy / Irradiation

• Not validated; some are rejected; remain experimental

3. Emerging Therapies (2025)

• First FDA-approved treatment specifically for RRP
• Off-the-shelf AdenoVerse gene therapy designed to elicit HPV-6/11-specific immune responses
• ~50% of treated adults required no additional surgeries over the following year with durable benefit

• DNA immunotherapy (DNA medicine) targeting HPV-6/11
• BLA rolling submission completed November 2025; under FDA Accelerated Approval review

Tracheotomy — Special Consideration

• Strongly discouraged in JORRP
• History of tracheotomy correlates with: more frequent surgeries, increased tracheal involvement, and worse outcome
• If unavoidable (critical airway obstruction not manageable otherwise), it becomes a last resort
• Promotes distal papilloma seeding along the tracheobronchial tree

Malignant Transformation

• Rare but recognized — occurs in ~1–4% of RRP cases
• Risk factors:
  • HPV-16 or HPV-18 (vs. 6/11)
  • Prior irradiation (historically used, now contraindicated)
  • Tobacco use
  • Immunosuppression
• Results in squamous cell carcinoma of the larynx, trachea, or lung

Prevention — HPV Vaccination

• Vaccinating women of reproductive age with Gardasil 9 before first sexual exposure prevents vertical transmission
• U.S. data from 2015–2020 show meaningful reductions in new JORRP cases following vaccine introduction
• Prevention remains the most powerful intervention available

Prognosis and Natural History

Summary of Key Points

• Cummings Otolaryngology Head and Neck Surgery, Chapter 60, pp. 1131–1133
• "Juvenile onset recurrent respiratory papillomatosis: What do we know in 2024?" PMC11088349
• Chinese guideline for the diagnosis and treatment of JORRP (2024) PMC11998182
• Jacobsen et al., Acta Otolaryngol 2025 — HPV vaccination and declining JORRP incidence (PMID 39611396)
• Ovcinnikova et al., Respir Res 2024 — Systematic review of epidemiology and burden (PMID 39696284)
• RRPF Research News (FDA approval of Papzimeos, August 2025)